GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate. / Leurs, Ulrike; Lajkó, Eszter; Mező, Gábor; Orbán, Erika; Öhlschläger, Peter; Marquardt, Andreas; Kőhidai, László; Manea, Marilena.

I: European Journal of Medicinal Chemistry, Bind 52, 06.2012, s. 173-83.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Leurs, U, Lajkó, E, Mező, G, Orbán, E, Öhlschläger, P, Marquardt, A, Kőhidai, L & Manea, M 2012, 'GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate', European Journal of Medicinal Chemistry, bind 52, s. 173-83. https://doi.org/10.1016/j.ejmech.2012.03.016

APA

Leurs, U., Lajkó, E., Mező, G., Orbán, E., Öhlschläger, P., Marquardt, A., ... Manea, M. (2012). GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate. European Journal of Medicinal Chemistry, 52, 173-83. https://doi.org/10.1016/j.ejmech.2012.03.016

Vancouver

Leurs U, Lajkó E, Mező G, Orbán E, Öhlschläger P, Marquardt A o.a. GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate. European Journal of Medicinal Chemistry. 2012 jun;52:173-83. https://doi.org/10.1016/j.ejmech.2012.03.016

Author

Leurs, Ulrike ; Lajkó, Eszter ; Mező, Gábor ; Orbán, Erika ; Öhlschläger, Peter ; Marquardt, Andreas ; Kőhidai, László ; Manea, Marilena. / GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate. I: European Journal of Medicinal Chemistry. 2012 ; Bind 52. s. 173-83.

Bibtex

@article{3b4b0b22ff22476a8d61b60ae23ead7b,
title = "GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate",
abstract = "Here we report on the design, synthesis and biochemical characterization of multifunctional bioconjugates containing two chemotherapeutic agents, daunorubicin and methotrexate, coupled to the GnRH-III decapeptide, which served as a targeting moiety. This represents a possible approach to increase the receptor mediated tumor targeting and consequently the cytostatic effect of anticancer drug-peptide bioconjugates. The multifunctional bioconjugates were prepared according to two drug design approaches recently developed by our group. Both bifunctional GnRH-III derivatives, [(4)Lys]-GnRH-III (Glp-His-Trp-Lys-His-Asp-Trp-Lys-Pro-Gly-NH(2)) and [(8)Lys(Lys)]-GnRH-III (Glp-His-Trp-Ser-His-Asp-Trp-Lys(Lys)-Pro-Gly-NH(2)), contain two free amino groups suitable for the attachment of two anticancer drugs, such as methotrexate and daunorubicin. The drugs were chosen with respect to their different mechanisms of action, with the goal of increasing the antitumor effect of the bioconjugates. The in vitro cytostatic effect of the bioconjugates was determined on MCF-7 human breast, HT-29 human colon and LNCaP human prostate cancer cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Their in vitro stability/degradation in human serum and in the presence of rat liver lysosomal homogenate was investigated by liquid chromatography in combination with mass spectrometry. The influence of the multifunctional bioconjugates on the cell adhesion and cell proliferation was studied on Mono Mac 6 human leukemic monocytes. It was found that (1) all synthesized bioconjugates had in vitro cytostatic effect; (2) they were stable in human serum for at least 24 h; (3) they were hydrolyzed in the presence of lysosomal homogenate and (4) they exerted a moderate cell-cell adhesion inducing effect. These results demonstrate that multifunctional bioconjugates containing two different anticancer drugs attached to the same GnRH-III targeting moiety could be successfully prepared and resulted in higher in vitro cytostatic effect than the monofunctional bioconjugates containing either methotrexate or daunorubicin, in particular on HT-29 human colon cancer cells.",
author = "Ulrike Leurs and Eszter Lajk{\'o} and G{\'a}bor Mező and Erika Orb{\'a}n and Peter {\"O}hlschl{\"a}ger and Andreas Marquardt and L{\'a}szl{\'o} Kőhidai and Marilena Manea",
note = "Copyright {\circledC} 2012 Elsevier Masson SAS. All rights reserved.",
year = "2012",
month = "6",
doi = "10.1016/j.ejmech.2012.03.016",
language = "English",
volume = "52",
pages = "173--83",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson",

}

RIS

TY - JOUR

T1 - GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate

AU - Leurs, Ulrike

AU - Lajkó, Eszter

AU - Mező, Gábor

AU - Orbán, Erika

AU - Öhlschläger, Peter

AU - Marquardt, Andreas

AU - Kőhidai, László

AU - Manea, Marilena

N1 - Copyright © 2012 Elsevier Masson SAS. All rights reserved.

PY - 2012/6

Y1 - 2012/6

N2 - Here we report on the design, synthesis and biochemical characterization of multifunctional bioconjugates containing two chemotherapeutic agents, daunorubicin and methotrexate, coupled to the GnRH-III decapeptide, which served as a targeting moiety. This represents a possible approach to increase the receptor mediated tumor targeting and consequently the cytostatic effect of anticancer drug-peptide bioconjugates. The multifunctional bioconjugates were prepared according to two drug design approaches recently developed by our group. Both bifunctional GnRH-III derivatives, [(4)Lys]-GnRH-III (Glp-His-Trp-Lys-His-Asp-Trp-Lys-Pro-Gly-NH(2)) and [(8)Lys(Lys)]-GnRH-III (Glp-His-Trp-Ser-His-Asp-Trp-Lys(Lys)-Pro-Gly-NH(2)), contain two free amino groups suitable for the attachment of two anticancer drugs, such as methotrexate and daunorubicin. The drugs were chosen with respect to their different mechanisms of action, with the goal of increasing the antitumor effect of the bioconjugates. The in vitro cytostatic effect of the bioconjugates was determined on MCF-7 human breast, HT-29 human colon and LNCaP human prostate cancer cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Their in vitro stability/degradation in human serum and in the presence of rat liver lysosomal homogenate was investigated by liquid chromatography in combination with mass spectrometry. The influence of the multifunctional bioconjugates on the cell adhesion and cell proliferation was studied on Mono Mac 6 human leukemic monocytes. It was found that (1) all synthesized bioconjugates had in vitro cytostatic effect; (2) they were stable in human serum for at least 24 h; (3) they were hydrolyzed in the presence of lysosomal homogenate and (4) they exerted a moderate cell-cell adhesion inducing effect. These results demonstrate that multifunctional bioconjugates containing two different anticancer drugs attached to the same GnRH-III targeting moiety could be successfully prepared and resulted in higher in vitro cytostatic effect than the monofunctional bioconjugates containing either methotrexate or daunorubicin, in particular on HT-29 human colon cancer cells.

AB - Here we report on the design, synthesis and biochemical characterization of multifunctional bioconjugates containing two chemotherapeutic agents, daunorubicin and methotrexate, coupled to the GnRH-III decapeptide, which served as a targeting moiety. This represents a possible approach to increase the receptor mediated tumor targeting and consequently the cytostatic effect of anticancer drug-peptide bioconjugates. The multifunctional bioconjugates were prepared according to two drug design approaches recently developed by our group. Both bifunctional GnRH-III derivatives, [(4)Lys]-GnRH-III (Glp-His-Trp-Lys-His-Asp-Trp-Lys-Pro-Gly-NH(2)) and [(8)Lys(Lys)]-GnRH-III (Glp-His-Trp-Ser-His-Asp-Trp-Lys(Lys)-Pro-Gly-NH(2)), contain two free amino groups suitable for the attachment of two anticancer drugs, such as methotrexate and daunorubicin. The drugs were chosen with respect to their different mechanisms of action, with the goal of increasing the antitumor effect of the bioconjugates. The in vitro cytostatic effect of the bioconjugates was determined on MCF-7 human breast, HT-29 human colon and LNCaP human prostate cancer cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Their in vitro stability/degradation in human serum and in the presence of rat liver lysosomal homogenate was investigated by liquid chromatography in combination with mass spectrometry. The influence of the multifunctional bioconjugates on the cell adhesion and cell proliferation was studied on Mono Mac 6 human leukemic monocytes. It was found that (1) all synthesized bioconjugates had in vitro cytostatic effect; (2) they were stable in human serum for at least 24 h; (3) they were hydrolyzed in the presence of lysosomal homogenate and (4) they exerted a moderate cell-cell adhesion inducing effect. These results demonstrate that multifunctional bioconjugates containing two different anticancer drugs attached to the same GnRH-III targeting moiety could be successfully prepared and resulted in higher in vitro cytostatic effect than the monofunctional bioconjugates containing either methotrexate or daunorubicin, in particular on HT-29 human colon cancer cells.

U2 - 10.1016/j.ejmech.2012.03.016

DO - 10.1016/j.ejmech.2012.03.016

M3 - Journal article

C2 - 22480495

VL - 52

SP - 173

EP - 183

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -

ID: 45967490